Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHM-2101
- Development stage
- Phase 2
- Lead developer
- Chimeric Therapies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
CHM-2101 is a third-generation autologous chimeric antigen receptor (CAR) T cell therapy targeting cadherin-17 (CDH17), a protein associated with poor prognosis and metastasis in gastrointestinal cancers. Developed by Chimeric Therapeutics and the University of Pennsylvania, this therapy incorporates both CD28 and 4-1BB co-stimulatory domains to enhance efficacy. It is designed for the treatment of advanced colorectal cancer, gastric cancer, and neuroendocrine tumors. Preclinical studies demonstrated that CHM-2101 could eradicate established tumors in multiple models without toxicity to normal tissues. The drug is currently being evaluated in Phase I/II clinical trials following FDA IND clearance[1][5][6][8].
- Other names
- Autologous anti-CDH17 CAR-T cells
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on CHM-2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHM-2101.